，这是一家开发AI代理以帮助制药公司管理药物研发的初创公司，ChatGPT的开发者独家向Axios透露了这一消息。
OpenAI has acquired Orchestra Bio, a startup building AI agents to help pharmaceutical companies manage drug development, the ChatGPT maker shared exclusively with Axios.
为何重要：竞争对手AI巨头OpenAI和Anthropic都在进军科学领域，因为它们希望超越编程和网络安全等核心竞争力进行拓展。
Why it matters: Rival AI giants OpenAI and Anthropic are both pushing into science as they look to expand beyond their core competencies in coding and cybersecurity.
现状： OpenAI表示，将把Orchestra的团队和技术整合到Rosalind中，这是其为生命科学研究人员设计的AI模型和工具套件。
State of play: OpenAI will integrate Orchestra's team and technology into Rosalind, its suite of AI models and tools designed for life sciences researchers, the company said.
- Orchestra的平台允许科学家将监控研究、跟踪药物研发时间表以及识别潜在延误等任务委派给AI代理。
• Orchestra's platform allows scientists to delegate tasks like monitoring studies, tracking drug development timelines and identifying potential delays to AI agents.
- 两家公司都旨在部署能够将科学发现与推进潜在疗法所需的决策和下一步行动相连接的代理。
• Both companies aim to deploy agents that can connect scientific findings with the decisions and next steps required to advance potential treatments.
- 收购的财务条款未披露。
• Financial terms of the acquisition were not disclosed.
深层含义： AI公司不仅希望提高生产力，还希望能够声称自己对治愈癌症、解决数学问题以及从根本上改变世界上每个关键行业负责。
Between the lines: AI companies don't just want to increase productivity, they want to say they are responsible for, say, curing cancer, solving math, and fundamentally changing every critical industry in the world.
- 这些雄心壮志推动了竞争对手AI实验室的收购行为。
• Those ambitions have fueled acquisitions from rival AI labs.
- 据《信息》报道，Anthropic在4月以约4亿美元收购了AI生物科技初创公司Coefficient Bio。
• Anthropic acquired AI biotech startup Coefficient Bio for roughly $400 million in April, according to The Information. Zoom in:
细节： OpenAI在4月推出了专门的GPT-Rosalind模型，以帮助研究人员解决生物学、化学和药物发现中的复杂问题。
OpenAI introduced its specialized GPT-Rosalind model in April to help researchers tackle complex problems in biology, chemistry and drug discovery.
- OpenAI还与诺和诺德和Moderna等制药巨头合作，将AI引入研发工作流程。
• OpenAI has also partnered with pharmaceutical giants including Novo Nordisk and Moderna to bring AI into research and development workflows.
- OpenAI表示，开发一种新药通常需要10到15年，它希望AI能够缩短这一时间表。Anthropic也在生命科学领域进行积极推进。
• OpenAI says developing a new medicine typically takes 10 to 15 years, a timeline it hopes AI can shorten. Anthropic has been making its own aggressive push into life sciences.
- 6月，Anthropic推出了Claude Science，这是一个由AI驱动的研究平台，可连接科学数据库、分析工具和专用代理。
• In June, Anthropic launched Claude Science, an AI-powered research platform that connects scientific databases, analysis tools and specialized agents.
- 9月，该公司宣布成立一家新的生物研究实验室，并表示Claude帮助发现了一种此前未知的、与CRISPR相似的酶系统，不过一些科学家称这些发现被夸大了，据彭博社报道。
• In September, the company announced a new biological research lab and said Claude had helped discover a previously unknown enzyme system with similarities to CRISPR, though some scientists said these finders were overblown, per Bloomberg. The bottom line:
核心要点：人工智能竞赛正从打造最佳模型转向将这种智能应用于各行各业。
The AI race is shifting from building the best models to applying that intelligence across industries.
- 几位人工智能投资者向Axios表示，随着人工智能公司上市，一个关键问题是它们能将业务拓展到多远的新市场。
• Several AI investors told Axios a key question as AI companies go public is how far they can expand into new markets.